Work

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-165979

Authors: Paolo Strati, Tae Min Kim, Alexey V Danilov, Chan Y. Cheah, Dok Hyun Yoon, Wojciech Jurczak, Shringi Sharma, Jeong Lim Yoon, Serena Arduini, Jamal Saeh, Richard F. Olsson, Gareth Gregory

Institutions: The University of Texas MD Anderson Cancer Center, Seoul National University Hospital, City Of Hope National Medical Center, The University of Western Australia, Sir Charles Gairdner Hospital, Asan Medical Center, The Maria Sklodowska-Curie National Research Institute of Oncology, AstraZeneca (United States), AstraZeneca (United Kingdom), AstraZeneca (Sweden), Monash Health, Monash University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310107747

FWCI: 1.133

Cites:

Cited by: 10

Related to: 10